Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study

[1]  B. Soliven,et al.  Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations , 2021, Journal of clinical medicine.

[2]  Yu Zhang,et al.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers , 2021, Clinical and translational science.

[3]  S. Tzartos,et al.  Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management , 2020, Frontiers in Neurology.

[4]  F. Shi,et al.  Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study , 2020, The Lancet regional health. Western Pacific.

[5]  A. Lascano,et al.  Update in immunosuppressive therapy of myasthenia gravis. , 2020, Autoimmunity reviews.

[6]  C. Cunningham-Rundles,et al.  Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations , 2020, Journal of Allergy and Clinical Immunology.

[7]  P. van Damme,et al.  ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab , 2020, Journal of Neurology.

[8]  Jacqueline A Palace,et al.  Myasthenia gravis. , 2020, Nature reviews. Disease primers.

[9]  L. Pearce,et al.  Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses , 2019, Science Advances.

[10]  A. Zuercher,et al.  Next-generation Fc receptor-targeting biologics for autoimmune diseases. , 2019, Autoimmunity reviews.

[11]  P. van Damme,et al.  Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis , 2019, Neurology.

[12]  T. Okado,et al.  Removal Characteristics of Immunoadsorption with the Tryptophan‐Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis , 2019, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[13]  A. Manning,et al.  M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study , 2018, Clinical pharmacology and therapeutics.

[14]  R. Lledo-Garcia,et al.  The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study , 2017, Science Translational Medicine.

[15]  M. Conaway,et al.  International clinimetric evaluation of the MG‐QOL15, resulting in slight revision and subsequent validation of the MG‐QOL15r , 2016, Muscle & nerve.

[16]  K. Mannan,et al.  Correlation between Serum Cholesterol and Serum Albumin Level in Childhood Nephrotic Syndrome , 2016 .

[17]  J. Howard,et al.  Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis , 2016, Autoimmunity.

[18]  Inger Sandlie,et al.  Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics , 2015, Front. Immunol..

[19]  G. Wolfe,et al.  Myasthenia gravis activities of daily living profile , 1999, Neurology.

[20]  R. Barohn,et al.  Reliability Testing of the Quantitative Myasthenia Gravis Score a , 1998, Annals of the New York Academy of Sciences.